Why Centrus Energy Stock Is in Free Fall Today

Centrus Energy reported Q4 2025 revenue of $146.2 million (vs. $147.1 million consensus), a 3.6% year-over-year decline, and diluted EPS of $0.79 versus analyst expectations of $1.63 and prior Q4 EPS of $3.20 (2024) and $3.58 (2023). The earnings shortfall sent shares sharply lower (down ~19.3% intraday), though the company’s backlog increased to $3.8 billion from $3.7 billion a year earlier, supporting longer-term contract visibility despite the near-term hit to profitability and investor sentiment.

Analysis

Market structure: Centrus (LEU) is a direct loser from the print — equity holders and short-term option sellers bear the brunt, while utilities and alternative HALEU suppliers (third‑party enrichers) are potential beneficiaries if Centrus delays deliveries. The $3.8bn backlog vs ~ $585m 2025 run‑rate implies ~6.5 years of revenue visibility, which supports long‑term pricing power, but today's miss signals execution and margin risk that will compress near‑term investor appetite and raise credit/working‑capital pressure.

Risk assessment: Near term (days) expect continued equity volatility and wider credit spreads for LEU; short term (weeks–months) the key tail risks are regulatory licensing delays, DOE contract reallocations, or a fabrication outage that could trigger contract penalties; long term (years) HALEU scarcity from SMR demand creates upside if Centrus executes. Hidden dependencies: DOE awards, enrichment cascade uptime, and customer financing posture — any one can flip revenue recognition and margins quickly. Catalysts: upcoming quarterly guidance, DOE/utility contract announcements, and uranium spot price moves.

Trade implications: Favor selective exposure to the commodity and avoid single‑name execution risk. Use a 3–9 month horizon for pair trades (long URA vs short LEU) to capture sector tailwinds while hedging execution risk. Options: exploit elevated IV by using defined‑risk verticals (buy 6‑month call spread if constructive; buy 3‑month put as protection if long).

Contrarian angle: The market may be over‑penalizing LEU’s equity for an execution miss while leaving intact ~6.5 years of contracted revenue; that asymmetry suggests a buy‑on‑confirmation setup rather than catch‑the‑fall. Historical parallels: project‑driven suppliers often trade down on timing misses then recover on contract confirmation — entry should be trigger‑based (guidance reconfirmation or DOE award) rather than pure bottom‑fishing.

Key Decisions for Investors

• Consider establishing a 2–3% portfolio long position in LEU within 4 weeks if the share price falls another 10–25% from current levels AND management reconfirms backlog ≥ $3.6bn and FY2026 revenue guidance within ±10% of consensus; increase to 5% only after a confirmed DOE/utility contract or two sequential quarters of execution improvement.
• Implement a 3–9 month pair trade: long URA ETF (2% portfolio weight) vs short LEU (1.5% weight) to capture uranium price upside while offsetting Centrus execution risk; rebalance after material contract announcements or quarterly results.
• Use options for defined risk: allocate 0.5–1% of portfolio to a 6‑month LEU call vertical (buy ATM, sell ~30% OTM) if bullish confirmation occurs; conversely buy a 3‑month 15–25% OTM LEU put (size 0.5%) as downside insurance if holding existing LEU shares.
• Reduce concentrated exposure to single‑vendor nuclear suppliers by ~25% over the next quarter and redeploy proceeds (2–4% portfolio) into diversified uranium exposure (URA) and regulated utility names to lower execution and counterparty risk.